Company unveils next-generation hygiene monitoring and multi-respiratory testing solutions setting new standards for speed, sensitivity and real-world impact
ProGnosis Biotech made a bold statement at Analytica 2026, one of the world’s premier exhibitions for laboratory technology, analysis and diagnostics. The event brought together industry leaders, innovators and global stakeholders providing a platform for thought leadership, strategic partnerships and a glimpse into the future of laboratory science.
At this year’s exhibition, ProGnosis Biotech presented two central pillars of its portfolio, hygiene monitoring and clinical diagnostics, demonstrating a clear vision for next-generation laboratory solutions.
Within the hygiene monitoring pillar, ATP-FemtoFlow stood out as a next-generation surface ATP detection system that delivers up to four times higher sensitivity than conventional ATP swab tests. This technology allows laboratories and industry professionals to detect even the smallest traces of biological, microbial and organic contamination quickly and reliably without adding complexity to their workflows. ATP-FemtoFlow is designed for the most demanding environments transforming hygiene monitoring into a precise and actionable process for food production, environmental monitoring and healthcare settings.
The clinical diagnostics pillar featured ProGnosis Biotech’s multi-respiratory disease testing solution capable of detecting up to five major respiratory viruses including COVID-19, Influenza A and B, Adenovirus and RSV from a single sample. By consolidating multiple tests into one streamlined process, the system accelerates results, supports faster clinical decision-making and optimises laboratory resources while maintaining high diagnostic reliability.
Analytica 2026 also highlighted the forces transforming laboratory science including artificial intelligence, digitalisation, automation, sustainability and advanced data management. ProGnosis Biotech is redefining innovation by delivering solutions that combine scientific excellence with practical usability enabling real-world impact from day one.
“Analytica 2026 confirmed a profound shift in our industry,” said Georgios Papageorgiou, Chief Operating Officer and Co-Founder of ProGnosis Biotech. “Innovation is no longer enough on its own. It must translate into solutions that are fast, practical and decision-enabling. ATP-FemtoFlow and our multi-respiratory testing platform demonstrate this philosophy by turning advanced science into measurable impact in everyday laboratory and healthcare settings. We are raising the standard for what professionals can expect from diagnostic technologies.”
By participating in Analytica 2026, ProGnosis Biotech reinforced its position as a category-defining leader committed to bridging the gap between scientific expertise and practical application. The event provided an important opportunity to showcase innovation priorities, strengthen strategic partnerships and actively contribute to shaping the next generation of laboratory and diagnostic solutions worldwide.
